Karthick Vishwanathan

Karthick Vishwanathan

Auto-generated profile, based on publicly available information

Karthick Vishwanathan

Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Waltham Massachusetts USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MJMartin Johnson
Martin Johnson
CTCarlos Traynor
Carlos Traynor
KVKarthick Vishwanathan
Karthick Vishwanathan
POPhilip Overend
Philip Overend
RHRyan Hartmaier
Ryan Hartmaier
SRSuresh S. Ramalingam
Suresh S. Ramalingam

26 December 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
WQWenlian Qiao
Wenlian Qiao
ASAzar Shahraz
Azar Shahraz
KVKarthick Vishwanathan
Karthick Vishwanathan
ASAarti Sawant‐Basak
Aarti Sawant‐Basak
While the subcutaneous (SC) route of administration (RoA) is more patient‐centric and cost‐effective than the intravenous (IV) RoA, the Switch‐to‐SC paradigm has been employed in oncology antibody drug development. T cell engagers (TCEs) are typically highly potent and efficacious at low doses, supporting their suitability for the Direct‐to‐SC in FIH paradigm. This perspective discusses anticipated clinical pharmacology challenges associated with the Direct‐to‐SC in FIH paradigm and provides potential solutions to address the challenges.